(Q37543446)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19583455%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

review article

1 reference

title

Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19583455%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19583455%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Claudine M Baldwin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19583455%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

1 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19583455%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19583455%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19583455%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19583455%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

1373-1401

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19583455%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003495-200969100-00007

2 February 2020

exact match

0 references

cites work

Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969100-00007

Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969100-00007

Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969100-00007

Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969100-00007

Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969100-00007

Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969100-00007

Proton pump inhibitors: balancing the benefits and potential fracture risks

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969100-00007

Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969100-00007

Molecular mechanisms in therapy of acid-related diseases

21 January 2018

1 reference

12 December 2020

"Best practice' for Helicobacter pylori eradication in the primary care setting.

1 reference

12 December 2020

Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism

1 reference

12 December 2020

Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease

1 reference

12 December 2020

Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects

1 reference

12 December 2020

1 reference

12 December 2020

Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication

1 reference

12 December 2020

Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group

1 reference

12 December 2020

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

1 reference

12 December 2020

Gastro-oesophageal reflux disease in adults: Guidelines for clinicians

1 reference

12 December 2020

Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection

1 reference

12 December 2020

Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease

1 reference

12 December 2020

Rabeprazole-induced acute interstitial nephritis

1 reference

12 December 2020

Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease

1 reference

12 December 2020

Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.

1 reference

12 December 2020

Medical management of gastroesophageal reflux disease

1 reference

12 December 2020

Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group

1 reference

12 December 2020

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

1 reference

12 December 2020

Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.

1 reference

12 December 2020

Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a mainten

1 reference

12 December 2020

The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis

1 reference

12 December 2020

Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?

1 reference

12 December 2020

Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers

1 reference

12 December 2020

Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases

1 reference

12 December 2020

Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors

1 reference

12 December 2020

Rabeprazole: an update of its use in acid-related disorders

1 reference

12 December 2020

A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years

1 reference

12 December 2020

Potent gastric acid inhibition in Helicobacter pylori eradication

1 reference

12 December 2020

Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa

1 reference

12 December 2020

Guide to the use of proton pump inhibitors in adult patients

1 reference

12 December 2020

On-demand therapy for gastroesophageal reflux disease

1 reference

12 December 2020

Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study

1 reference

12 December 2020

Review article: drug interactions with agents used to treat acid-related diseases

1 reference

12 December 2020

Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.

1 reference

12 December 2020

Lansoprazole: an update of its place in the management of acid-related disorders

1 reference

12 December 2020

Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study

1 reference

12 December 2020

Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation

1 reference

12 December 2020

An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion

1 reference

12 December 2020

Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.

1 reference

12 December 2020

Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

1 reference

12 December 2020

Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers.

1 reference

12 December 2020

Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease

1 reference

12 December 2020

Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs

1 reference

12 December 2020

Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment

1 reference

12 December 2020

Pharmacokinetic drug interaction profiles of proton pump inhibitors

1 reference

12 December 2020

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

1 reference

12 December 2020

Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication.

1 reference

12 December 2020

Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders

1 reference

12 December 2020

Review article: the pharmacology of rabeprazole

1 reference

12 December 2020

Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study

1 reference

12 December 2020

A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease

1 reference

12 December 2020

Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole

1 reference

12 December 2020

Rabeprazole: a review of its use in acid-related gastrointestinal disorders

1 reference

12 December 2020

In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori

1 reference

12 December 2020

Seven-day therapy for Helicobacter pylori in the United States

1 reference

12 December 2020

Management of gastro-oesophageal reflux disease in general practice

1 reference

12 December 2020

Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults

1 reference

12 December 2020

Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.

1 reference

12 December 2020

Esomeprazole 20mg provides more effective intragastric Acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers

1 reference

12 December 2020

Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori

1 reference

12 December 2020

Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin

1 reference

12 December 2020

CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole

1 reference

12 December 2020

Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group

1 reference

12 December 2020

Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms

1 reference

12 December 2020

Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn

1 reference

12 December 2020

Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects

1 reference

12 December 2020

Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States

1 reference

12 December 2020

Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group

1 reference

12 December 2020

Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers.

1 reference

12 December 2020

Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial

1 reference

12 December 2020

Review article: the pharmacokinetics of rabeprazole in health and disease

1 reference

12 December 2020

Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes

1 reference

12 December 2020

Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know

1 reference

12 December 2020

Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study.

1 reference

12 December 2020

Rabeprazole and psychiatric symptoms.

1 reference

12 December 2020